Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19.
CRP
OPN
PCT
SARS-CoV-2
coronavirus disease 2019
death
mechanical ventilation
outcomes
procalcitonin
renal replacement therapy
risk prediction
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
30 Aug 2021
30 Aug 2021
Historique:
received:
07
07
2021
revised:
16
08
2021
accepted:
26
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Severe coronavirus disease 2019 (COVID-19) is the result of a hyper-inflammatory reaction to the severe acute respiratory syndrome coronavirus 2. The biomarkers of inflammation have been used to risk-stratify patients with COVID-19. Osteopontin (OPN) is an integrin-binding glyco-phosphoprotein involved in the modulation of leukocyte activation; its levels are associated with worse outcomes in patients with sepsis. Whether OPN levels predict outcomes in COVID-19 is unknown. We measured OPN levels in serum of 341 hospitalized COVID-19 patients collected within 48 h from admission. We characterized the determinants of OPN levels and examined their association with in-hospital outcomes; notably death, need for mechanical ventilation, and need for renal replacement therapy (RRT) and as a composite outcome. The risk discrimination ability of OPN was compared with other inflammatory biomarkers. Patients with COVID-19 (mean age 60, 61.9% male, 27.0% blacks) had significantly higher levels of serum OPN compared to healthy volunteers (96.63 vs. 16.56 ng/mL, Higher OPN levels are associated with increased odds of death and mechanical ventilation in patients with COVID-19, however, their utility in triage is questionable.
Sections du résumé
BACKGROUND
BACKGROUND
Severe coronavirus disease 2019 (COVID-19) is the result of a hyper-inflammatory reaction to the severe acute respiratory syndrome coronavirus 2. The biomarkers of inflammation have been used to risk-stratify patients with COVID-19. Osteopontin (OPN) is an integrin-binding glyco-phosphoprotein involved in the modulation of leukocyte activation; its levels are associated with worse outcomes in patients with sepsis. Whether OPN levels predict outcomes in COVID-19 is unknown.
METHODS
METHODS
We measured OPN levels in serum of 341 hospitalized COVID-19 patients collected within 48 h from admission. We characterized the determinants of OPN levels and examined their association with in-hospital outcomes; notably death, need for mechanical ventilation, and need for renal replacement therapy (RRT) and as a composite outcome. The risk discrimination ability of OPN was compared with other inflammatory biomarkers.
RESULTS
RESULTS
Patients with COVID-19 (mean age 60, 61.9% male, 27.0% blacks) had significantly higher levels of serum OPN compared to healthy volunteers (96.63 vs. 16.56 ng/mL,
CONCLUSION
CONCLUSIONS
Higher OPN levels are associated with increased odds of death and mechanical ventilation in patients with COVID-19, however, their utility in triage is questionable.
Identifiants
pubmed: 34501358
pii: jcm10173907
doi: 10.3390/jcm10173907
pmc: PMC8432103
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK119083
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL153384
Pays : United States
Organisme : Wellcome Trust
ID : 110043
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : U2C DK110768
Pays : United States
Organisme : NHLBI NIH HHS
ID : 1R01HL153384-01
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK128012
Pays : United States
Références
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Wien Klin Wochenschr. 2021 Apr;133(7-8):298-302
pubmed: 33369698
Respir Med. 2005 Jan;99(1):111-7
pubmed: 15672859
Lancet. 2020 Mar 28;395(10229):1014-1015
pubmed: 32197108
EMBO Mol Med. 2021 May 7;13(5):e14124
pubmed: 33787012
Lancet Respir Med. 2021 May;9(5):511-521
pubmed: 33676589
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Am Soc Nephrol. 2020 Nov;31(11):2725-2735
pubmed: 32963090
Crit Care. 2015 Jun 26;19:271
pubmed: 26111529
J Clin Med. 2018 Oct 26;7(11):
pubmed: 30373147
Front Immunol. 2017 Mar 23;8:321
pubmed: 28386258
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45
pubmed: 18952487
Lancet Respir Med. 2020 Dec;8(12):1233-1244
pubmed: 33075298
Cells. 2019 Feb 18;8(2):
pubmed: 30781721
J Hepatol. 2017 Oct;67(4):749-757
pubmed: 28668580
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr;5(2):388-402
pubmed: 33585800
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Respirology. 2010 Oct;15(7):1111-21
pubmed: 20796249
Eur J Intern Med. 2020 Aug;78:113-120
pubmed: 32409206